title: Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Wick
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D016503:Drug Delivery Systems; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013873:Thionucleotides / Q000008:administration & dosage*; D053781:Transforming Growth Factor beta2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009838:Oligodeoxyribonucleotides; D013873:Thionucleotides; D053781:Transforming Growth Factor beta2; C525712:Trabedersen